[go: up one dir, main page]

WO2008121261A3 - Traitement efficace de tumeurs et de cancer au moyen de promédicaments de la triciribine - Google Patents

Traitement efficace de tumeurs et de cancer au moyen de promédicaments de la triciribine Download PDF

Info

Publication number
WO2008121261A3
WO2008121261A3 PCT/US2008/003853 US2008003853W WO2008121261A3 WO 2008121261 A3 WO2008121261 A3 WO 2008121261A3 US 2008003853 W US2008003853 W US 2008003853W WO 2008121261 A3 WO2008121261 A3 WO 2008121261A3
Authority
WO
WIPO (PCT)
Prior art keywords
prodrugs
tumors
cancer
treatment
triciribin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/003853
Other languages
English (en)
Other versions
WO2008121261A2 (fr
Inventor
Lawrence Akinsanmi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VIOQUEST PHARMACEUTICALS Inc
Original Assignee
VIOQUEST PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIOQUEST PHARMACEUTICALS Inc filed Critical VIOQUEST PHARMACEUTICALS Inc
Publication of WO2008121261A2 publication Critical patent/WO2008121261A2/fr
Publication of WO2008121261A3 publication Critical patent/WO2008121261A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux promédicaments de la triciribine et de substances apparentées, ainsi que des régimes thérapeutiques de promédicaments de la triciribine et de substances apparentées et des compositions pour le traitement de tumeurs, de cancer et d'autres troubles associés à une prolifération cellulaire anormale. L'invention concerne en outre des formulations orales de promédicaments à biodisponibilité accrue, fournissant ainsi une nouvelle voie d'administration avec les avantages cliniques qui en découlent en termes de facilité d'administration.
PCT/US2008/003853 2007-03-28 2008-03-25 Traitement efficace de tumeurs et de cancer au moyen de promédicaments de la triciribine Ceased WO2008121261A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90730507P 2007-03-28 2007-03-28
US60/907,305 2007-03-28

Publications (2)

Publication Number Publication Date
WO2008121261A2 WO2008121261A2 (fr) 2008-10-09
WO2008121261A3 true WO2008121261A3 (fr) 2008-12-24

Family

ID=39712321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003853 Ceased WO2008121261A2 (fr) 2007-03-28 2008-03-25 Traitement efficace de tumeurs et de cancer au moyen de promédicaments de la triciribine

Country Status (2)

Country Link
TW (1) TW200902034A (fr)
WO (1) WO2008121261A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2798185T3 (es) 2012-04-26 2020-12-09 Massachusetts Gen Hospital Agentes y métodos para el tratamiento y prevención de queratosis seborreica
US10508309B2 (en) 2013-05-17 2019-12-17 The General Hospital Corporation Methods for detecting and treating variants of seborrheic keratoses
WO2018067424A1 (fr) * 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibiteurs de l'adénosine 5'-nucléotidase
WO2021097401A1 (fr) * 2019-11-14 2021-05-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Polythérapie avec un inhibiteur d'activation de protéine kinase b pour traiter le cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4123524A (en) * 1977-06-08 1978-10-31 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-C]pyridazine-5'-phosphate as a novel compound and its utility against L-1210 mouse leukemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4123524A (en) * 1977-06-08 1978-10-31 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-C]pyridazine-5'-phosphate as a novel compound and its utility against L-1210 mouse leukemia

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. J. BODNER ET AL.: "Induction of differentiation of human promyelocytic leukemia cells (HL-60) by nucleosides and methotrexate", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 67, no. 5, 1981, US DEPT. OF HEALTH, EDUCATION AND WELFARE, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH, BETHESDA, MD; US, pages 1025 - 1030 *
A. R. PORCARI ET AL.: "An Improved Total Synthesis of Triciribine: A Tricyclic Nucleoside with Antineoplastic and Antiviral Properties", NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS., vol. 23, no. 1, 2004, TAYLOR & FRANCIS, PHILADELPHIA, PA.; US, pages 31 - 39 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 12 May 1984 (1984-05-12), XP002499547, retrieved from STN Database accession no. 1982:32363 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 February 2004 (2004-02-18), XP002499546, retrieved from STN Database accession no. 2004:131615 *
PORCARI, A. R. ET AL.: "6-N-Acyltriciribine Analogues: Structure-Activity Relationship between Acyl Carbon Chain Length and Activity against HIV-1", JOURNAL OF MEDICINAL CHEMISTRY., vol. 43, no. 12, 2000, AMERICAN CHEMICAL SOCIETY. WASHINGTON; US, pages 2457 - 2463, XP002499362 *

Also Published As

Publication number Publication date
WO2008121261A2 (fr) 2008-10-09
TW200902034A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
EP4327888A3 (fr) Formulations orales d'analogues de cytidine et leurs procédés d'utilisation
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
WO2009064460A3 (fr) Systèmes de délivrance aux voies gastro-intestinales
EP2963031A3 (fr) Promédicaments de tétrahydrocannabinol, compositions contenant des promédicaments de tétrahydrocannabinol et méthodes d'utilisation de celles-ci
BRPI0916356A2 (fr)
MY147890A (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer
WO2008028193A3 (fr) Formulations orales d'analogues de cytidine administrées dans le côlon
WO2005116086A3 (fr) Glucosamine et promédicaments mutuels anti-inflammatoires, compositions et procédés à base de glucosamine
PH12014501082B1 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2009071480A3 (fr) Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase
UA95975C2 (ru) N-метиламинометилизоиндольные соединения, композиции, содержащие их, и способы их применения
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
WO2009146216A3 (fr) Modulateurs d’inflammation antioxydant : nouveaux dérivés d’acide oléanolique
MX2010001242A (es) Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos.
WO2008020027A3 (fr) Utilisation de composés et de dérivés du 2,5-dihydroxybenzène pour le traitement du cancer de la peau
TN2011000172A1 (en) Therapeutic antiviral peptides
MY145795A (en) Pyrazoline compounds
WO2009071690A3 (fr) Dérivés d'oxindole à double substitution en positions 5 et 6 et leur utilisation pour traiter des maladies liées à la vasopressine
WO2011150201A3 (fr) Composés azolylamide et leurs procédés d'utilisation
IL202111A0 (en) Formulations for the oral administration of therapeutic agents and related methods
MX2012007217A (es) Derivados de (metilsulfonil) etilbenceno isoindolina y sus usos terapeuticos.
MX2010001243A (es) Composicion anti-inflamatoria.
WO2008121261A3 (fr) Traitement efficace de tumeurs et de cancer au moyen de promédicaments de la triciribine
WO2008004100A9 (fr) Composés thérapeutiques
WO2011039675A3 (fr) Formes posologiques thérapeutiques transdermiques de latrepirdine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742227

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1)EPC (EPOFORM 1205A DATED 08.03.2010

122 Ep: pct application non-entry in european phase

Ref document number: 08742227

Country of ref document: EP

Kind code of ref document: A2